Schizophrenia Clinical Trials in Los Angeles

Showing 81-98 of 98 trials

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

NCT00300963

The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.

Schizophrenia

GlaxoSmithKline275 participantsStarted Dec 2004

Little Rock, Arkansas, United States • Anaheim, California, United States • Cerritos, California, United States +17 more locations

COMPLETEDPHASE16.3 miles

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

NCT01376076

This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.

Schizophrenia

Forest Laboratories129 participantsStarted Jun 2011

Glendale, California, United States • Long Beach, California, United States • Willingboro, New Jersey, United States +1 more locations

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Schizophrenia Trials in Other Cities

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

A Long-Term, Open-Label, Study on Schizophrenia

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Other Conditions in Los Angeles